Showing 3611-3620 of 5773 results for "".
- AEYE Health Receives FDA Clearance for AI-Based Autonomous Screening for Referable Diabetic Retinopathyhttps://modernod.com/news/aeye-health-receives-fda-clearance-for-ai-based-autonomous-screening-for-referable-diabetic-retinopathy/2481245/AEYE Health announced that it received a 510(k) clearance from the FDA to market its diagnostic screening system for diabetic retinopathy. Screening diabetics for retinopathy using AI has recently become reimbursable in the United States using the newly approved CPT
- ViaLase Makes Several Appointments to its Executive Teamhttps://modernod.com/news/vialase-makes-several-appointments-to-its-executive-team/2481244/ViaLase announced the appointments of Tom Frinzi as Executive Chairman of the Board; Richard Lewis, MD, as Chief Medical Officer; Shawn O'Neil as Chief Commercial Officer; and Brendan O'Herlihy as Vice President, Global Commercial Operations. The executives w
- EssilorLuxottica Supports New WSPOS Independent Medical Education Program on Myopia Managementhttps://modernod.com/news/essilorluxottica-supports-new-wspos-independent-medical-education-program-on-myopia-management/2481243/EssilorLuxottica announced it is supporting the World Society of Paediatric Ophthalmology and Strabismus (WSPOS) independent medical education program on myopia management, as a gold level supporter, which will be launched on November 19 and 20, at 2-4pm GMT. The key goals of this progr
- Heru Surpasses Clinical Milestone of 100,000 Eyes Examinedhttps://modernod.com/news/heru-surpasses-clinical-milestone-of-100000-eyes-examined/2481242/Heru announced that it has passed the clinical milestone of over 100,000 patient eyes that have been examined using its wearable technology since the company’s commercial launch a little over a year ago. “We are thrilled to see the rapid adoption of the Heru platform,&r
- Nidek Launches the NT-1p Non-Contact Tono/Pachymeterhttps://modernod.com/news/nidek-launches-the-nt-1p-non-contact-tonopachymeter/2481241/Nidek announced the launch of the NT-1p Non-Contact Tono/Pachymeter. The NT-1p is an innovative device that fully automates reliable non-contact tonometry and pachymetry. By placing the chin on the chinrest, the NT-1p automatically detects the position of the eyes and begins measurement without p
- Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseaseshttps://modernod.com/news/opus-genetics-sponsors-uni-rare-natural-history-study-for-people-with-inherited-retinal-diseases/2481239/Opus Genetics announced the company will co-sponsor the Uni-Rare Study, a new natural history study for approximately 1,500 people with mutations in one of more than 300 rare genes associated with inherited retinal diseases (IRDs). The two-part Uni-Rare Study is being launched to charac
- Harrow Launches Atropine.comhttps://modernod.com/news/harrow-launches-atropinecom/2481236/Harrow announced the launch of atropine.com, an ordering and marketing portal designed specifically for prescribers interested in compounded atropine formulations. All atropine.com, prescriptions will be dispensed through Harrow’s wholly owned
- FDA Accepts Tarsus' New Drug Application for TP-03 for Treatment of Demodex Blepharitishttps://modernod.com/news/fda-accepts-tarsus-new-drug-application-for-tp-03-for-treatment-of-demodex-blepharitis/2481235/As part of its third quarter earnings report, Tarsus Pharmaceuticals announced that the FDA has accepted the company's new drug application (NDA) for TP-03 for the treatment of Demodex blepharitis. The Prescription Drug User Fee Act (PDUFA) target action da
- Viatris Acquires Oyster Point Pharmahttps://modernod.com/news/viatris-acquires-oyster-point-pharma/2481230/Viatris, a global health care company, announced it is acquiring Oyster Point Pharma, maker of Tyrvaya nasal spray, for $11 per share in cash, plus contingent payments up to $2 per share based on the achievement of specified performance targets. The acquisition of Oyster Point
- Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officerhttps://modernod.com/news/atsena-therapeutics-expands-leadership-team-with-appointment-of-lis-leiderman-md-mba-as-chief-financial-officer-and-chief-business-officer/2481229/Atsena Therapeutics announced the appointment of Elisabeth (Lis) Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer. Dr. Leiderman has more than 15 years of finance, business development and strategy experience in the life sciences industry, most recently with gene the